Skip to main content

Polyarticular Juvenile Idiopathic Arthritis News

Related terms: Polyarticular JIA

FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra

JERSEY CITY, N.J., Jan. 30, 2025 – Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Avtozma® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...

Shorla Oncology Announces U.S. FDA Expanded Approval of Jylamvo (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

CAMBRIDGE, Mass.--(BUSINESS WIRE) October 29, 2024 --Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has e...

FDA Approves Tyenne (tocilizumab-aazg), a Biosimilar to Actemra

March 7, 2024 – Fresenius Kabi, a global health care company that specializes in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Juvenile Idiopathic Arthritis

Related drug support groups

naproxen, methotrexate, Humira, Enbrel, Xeljanz, adalimumab, etanercept, Actemra, Cimzia